Improve support for children with diabetes in schools
Nine out of 10 children with diabetes lack support at school.
Promote age-appropriate education and psychosocial support
Only two out of 10 healthcare professionals routinely evaluate the psychosocial needs of the young people with diabetes and their families in their care.
Enhance parents and family-centred care and support
Four out of 10 parents and caregivers regularly felt overwhelmed by their child’s diabetes.
Facilitate peer support and networking through group activities and socialising with other young people with diabetes
Young people with diabetes as well as their parents and caregivers considered it important to talk to other young people with diabetes.
DAWN Youth is a new global programme that has been created to explore the attitudes, wishes and needs of young people affected by diabetes and their families. The programme hopes to guide the wider diabetes community to address the unmet needs of young people with diabetes and their families. Novo Nordisk in global partnership with International Diabetes Federation (IDF) and the International Society for Paediatric and Adolescent Diabetes (ISPAD) is now supporting the implementation of the survey findings into concrete national actions through national DAWN Youth boards, involving the different key stakeholders in each country to improve psychosocial support for people with diabetes through concerted advocacy, better practice sharing and concrete initiatives. For more information and background about the DAWN Youth initiative please visit dawnyouth.com. About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.